

**SESSION 1 POSTER PRESENTATION WEDNESDAY**  
**21 SEPTEMBER**

**Artificial Intelligence, Machine learning, and big data**

- P001** **Pharmacovigilance and Drug Safety Simulation Game: Innovative Approach for Training and Capacity building**  
Sefiani Houda, Moroccan Pharmacovigilance Centre, Rabat WHO Collaborating Centre, Morocco
- P002** **Embedding Digital Health, AI/ML and RWD in Managing Safety Risks and Enhancing Pharmacovigilance**  
Ghosh Rajesh, Genentech/Roche, USA
- P003** **Integration and Modeling of Translational Safety Data for Post-marketing Surveillance**  
Mestres Jordi, Chemotargets SL, Spain
- P004** **Online Interest in Cannabis and Psychedelics in Peri-pandemic Europe for Robust Pharmacovigilance**  
Al-Imam Ahmed, Poznan University of Medical Sciences, Poland
- P005** **Challenges of Local Medical Literature Monitoring and Possible Automation**  
Horilyk Artem, Pharmaceutical Education and Research Center (NPO PHARMA-ER), Ukraine
- P006** **Hyperacute Multisystem Toxicities with Immune Checkpoint Inhibitors in the FDA Adverse Event Reporting System: The Immune-Adversome**  
Raschi Emanuel, Alma Mater Studiorum – University of Bologna, Italy
- P007** **Temporal Evolution of Disproportionality Parameters: Study of the Case of Opioids in Relation to QTc Interval Prolongation**  
Keller Guillermo Alberto, Administración Nacional de Laboratorios e Institutos de Salud (ANLIS Malbran), Argentina
- P008** **Identifying Medications Underlying Communication Atypicalities: A Pharmacosurveillance Study Within the FDA Adverse Event Reporting System**  
Fusaroli Michele, University of Bologna, Italy
- P009** **Competitive Intelligence in Pharmacovigilance – A Case Study on Two Covid-19 Vaccines**  
Van Holle Lionel, OpenSourcePV, Belgium

---

**P010** [A Method for Identification of Renal Disease in Unstructured Clinical Narratives](#)

Davies Heather, University of Liverpool, United Kingdom

---

**P011** [Automated PV: What Are We Waiting for?](#)

Markey Jen, Insife, United Kingdom

---

**P012** [Automated De-identification of Case Narratives Using Deep Neural Networks for the UK Yellow Card System](#)

Meldau Eva-Lisa, Uppsala Monitoring Centre, Sweden

---

## Medication errors prevention

---

**P013** [Prescription Error: A Case of Metronidazole-induced Pancreatitis](#)

EL Aidli Sihem, University of Tunis El Manar Faculty of Medicine of Tunis -UR17ES12, Tunisia

---

**P014** [IoT and the Future of Signal Reporting, Medication Management, Clinical Research and Drug Safety with New Tools and Process](#)

Nurse Lloyd, Patient Advocate, Guyana

---

**P015** [Litigation Following Adverse Drug Reactions: Impact of Regulator Oversight – A Case Scenario of a Ceftriaxone Medication Error](#)

Byomire – Ndagije Helen Byomire, National Drug Authority, Uganda

---

**P017** [Clinical Impact of Pharmacotherapeutic Follow-up and Pharmaceutical Interventions in a Reference Hospital in Mexico City](#)

Maza Jose Antonio, Instituto Nacional de Cardiología Ignacio Chávez, Mexico

---

**P018** [Management of the Anticholinergic Burden in a Nursing Home in Sardinia](#)

Sanogo Seydou, ARES – Sardegna, Italy

---

**P019** [Measuring the Effectiveness of Electronic Prescription Systems in Reducing Medication Errors in Hospital Setting in Egypt](#)

Rostom Hadir, ISoP Egypt Chapter- MSA University, Egypt

---

**P020** [Paracetamol, a New Awareness on an Old Drug: A Survey Report on its Clinical Use in a Cancer Institute](#)

Calabro Concetta, Cancer Institute of Bari, Italy

---

**P021** [Assessment of the Quality of MedDRA Coding in a Sample of COVID-19 Vaccine Medication Error Data](#)

D'souza Joan, Institute of Pharmacovigilance, Switzerland

---

**P022** [Intoxications in a Pediatric Population: A Regional Retrospective Analysis](#)

Baiardi Giammarco, University of Genoa, Italy

---

- 
- 
- P023** **Identifying Adverse Drug Reactions from Free-text Dutch EHR in Hospitalized Patients with the Development of an Algorithm (IADDRESS)**  
Van De Burgt Britt, Catharina Hospital Eindhoven, Netherlands
- 
- P024** **Are Monitored Dosage Systems Causing Drug Related Problems? A Retrospective Analysis of Hospital Admissions**  
Stewart Leeanne, University of Birmingham, United Kingdom
- 
- P027** **Clinical Pharmacist Interventions in Critically Ill Patients with COVID-19**  
Hida Amina, Faculty of Medicine and Pharmacy of Rabat, Mohamed V Souissi University, Morocco
- 
- P028** **A Survey of Medication Errors Reported Due to Look-Alike Antiretroviral Therapy amongst Adult Clients at Mbagathi Hospital in Nairobi, Kenya**  
Wambura Catherine, Mbagathi Hospital, Kenya
- 
- P029** **Acute Liver Failure Following Therapeutic Doses of Paracetamol in Patients with Neuromuscular Diseases: A Preventable Medication Error**  
James Henry, Christian Medical College & Hospital, India
- 
- P030** **Children Voluntary Intoxications: Cases of Attempted Suicide**  
Mousannif Soumaya, Faculty of Medicine and Pharmacy of Rabat, Morocco
- 
- P031** **Is Preventability a Good Criterion for Medication Errors? A Proposal to Assess Continuous versus Binary Faultiness, Seriousness, Contribution to ADRs**  
Beckmann Juergen, Former head of the PV division of the German drug regulatory authority BfArM, Germany
- 
- P032** **COVID-19 Vaccination Errors During Tunisian Vaccination Campaign Collected from March 13, 2021 To September 29, 2021**  
El Aidli Sihem, University of Tunis El Manar Faculty of Medicine of Tunis -UR17ES12, Tunisia
- 
- P034** **Pre-Registration Evaluation of Proposed Invented Names for Human Medicinal Products: Saudi Food and Drug Authority Experience**  
Al Draihm Abdulaziz, Saudi Food and Drug Authority, Saudi Arabia
- 
- P035** **Overview of Paediatric Opioid Overdose Cases in France**  
Habib Hanawy Dina, Agence Nationale de Sécurité du Médicament et des Produits de Santé, France
- 
- P036** **Types and Frequency of Errors in the Preparation and Administration of Drugs in Pediatric Inpatient**  
Mousannif Soumaya, Faculty of Medicine and Pharmacy of Rabat, Morocco
- 
- P038** **Need of Drugs and Supplements Recognition in Oncological Patients: Role of the Clinical Pharmacologist**  
Stefanelli Berenice, University of Salerno, Italy
-

---

## Pharmacovigilance of biologics originator and biosimilar

---

- P040** [The Risk of Acute Kidney Injury in Bladder Cancer Patients Who Have Undergone Radical Cystectomy](#)  
Pan Xianying, Bristol Myers Squibb, USA
- 
- P041** [Safety Assessment of Biologics for Immune-Mediated Inflammatory Diseases Using Italian VALORE Healthcare Database Network and National Spontaneous Reporting System](#)  
Benoni Roberto, University of Verona, Italy
- 
- P042** [An Overview of the Pharmacovigilance System in Ghana](#)  
Onasanya Seun, University of KwaZulu-Natal, Westville Campus, South Africa
- 
- P043** [An Overview of the Pharmacovigilance System in Nigeria](#)  
Onasanya Seun, University of KwaZulu-Natal, Westville Campus, South Africa
- 
- P044** [Adverse Drug Effects Related to Biotherapy Used in the Treatment of Chronic Inflammatory Rheumatism at El Ayachi-Sale Hospital, Morocco](#)  
Lakhmiri Rim, Faculty of Medicine and Pharmacy, Mohammed V University Rabat, Morocco
- 
- P046** [Safety Profile of PCSK9 Inhibitors in Clinical Practice: An Italian Prospective Pharmacovigilance Study](#)  
De Sarro Giovambattista, University Magna Græcia of Catanzaro, Italy
- 
- P047** [Regorafenib-Related Myocardial Injury in Patient with HepatoCellular Carcinoma \(HCC\) Post Orthotopic Liver Transplant \(OLT\): Prevention and Management](#)  
Pascale Giulia, ASST GOM Niguarda, Italy
- 
- P048** [Meeting the Need: A Training Course for Data Safety Monitoring Board \(DSMB\) Members in LMIC](#)  
Sturkenboom Miriam, UMC Utrecht, Netherlands
- 
- P049** [Biologic Drugs: Pharmacovigilance Study Detecting Safety Profile and Therapy Effectiveness in Psoriasis and Psoriatic Arthritis](#)  
Pezzuto Benedetta, ASL Brindisi
- 
- P050** [Biological Medicines in Accidents with Poisonous Animals: Integrating Data from Various Sources](#)  
Keller Guillermo Alberto, Administración Nacional de Laboratorios e Institutos de Salud (ANLIS Malbran), Argentina
- 
- P051** [Use of Biological Drugs for Psoriasis: A Drug-utilization Study Using Tuscan Administrative Databanks](#)  
Giometto Sabrina, University of Pisa, Italy
-

- 
- P052** **Local Experience on Adalimumab and Etanercept Biosimilar Drugs: Safety and Efficacy Confirmation Encourages Rheumatologist Biosimilar Prescription**  
Babaglioni Giorgia, ASST Spedali Civili Brescia, Italy
- 
- P053** **Clinicians' and Patients' Involvement in Reporting Adverse Drug Reactions and Adherence to Treatment of Biological Drugs in Rheumatology, Dermatology, Gastroenterology**  
Ricciardelli Rita, Regional Pharmacovigilance Centre of Emilia-Romagna, Italy
- 
- P054** **A Rare Case of Polydactyly in a Newborn from Mother Affected by Multiple Sclerosis**  
Galuppi Chiara, ASST Spedali Civili of Brescia, Italy
- 
- P056** **Safety of Biologic Therapy for Crohn's Disease: An Active Pharmacovigilance Study**  
Ruffolo Livia, University of Catanzaro, Operative Unit of Clinical Pharmacology, Mater Domini University Hospital, Italy
- 
- P057** **Safety of Biological Drugs in Naïve Patients in Dermatological Field: Real Life Data from an Active Pharmacovigilance Project in Calabria Region**  
Verduci Chiara, University of Catanzaro, Operative Unit of Clinical Pharmacology, Mater Domini U, Italy
- 
- P058** **Venetoclax and Tumor Lysis Syndrome (TLS): Data Mining of the FDA Adverse Event Reporting System (FAERS) Database**  
Pascale Giulia, ASST GOM Niguarda, Italy
- 
- P060** **Secondary Depression Associated to TNF- $\alpha$  Inhibitors**  
Jabri Fatma Ezahra, University of Tunis el Manar – Faculty of Medicine of Tunis: research unit UR17ES12, Tunisia
- 
- P061** **Safety Profile of Dupilumab Approved for Chronic Rhinosinusitis with Nasal Polyposis: Analysis from the European Spontaneous Adverse Event Reporting System**  
Barbieri Maria Antonietta, University of Messina, Italy
- 
- P062** **Safety Profile of Tyrosine Kinase Inhibitors Approved for Gastrointestinal Stromal Tumors: Analysis from the European Spontaneous Adverse Event Reporting System**  
Barbieri Maria Antonietta, University of Messina, Italy
- 
- P063** **Safety Profile of Tyrosine Kinase Inhibitors Used in Non-Small-Cell Lung Cancer: An Analysis from The Italian Pharmacovigilance Database**  
Sorbara Emanuela Elisa, University of Messina, Italy
- 
- P064** **Focus on the Management of Reporting for Drug Ineffectiveness**  
Giannandrea Almagrazia, ASL BA, Italy
-

---

**P065 Real-World Pharmacovigilance Analysis of Lenvatinib Use in Qatar**

Omar Nabil Elhadi, National Centre for Cancer Care and Research,  
Hamad Medical Corporation, Qatar

---

**P066 Psoriasis Associated with Interferon Bêta-1b in a Multiple Sclerosis Patient with Positive Rechallenge**

ELAidli Sihem, University of Tunis El Manar Faculty of Medicine of Tunis –  
UR17ES12, Tunisia

---

**P067 Optic Neuritis: A Serious Adverse Effect of Etanercept**

Daghfous Riadh, Université Tunis el Manar Faculté de médecine de Tunis,  
Tunisia

---

**P068 Safety of Biologic Therapies for Severe Asthma: An Analysis of Adverse Reactions Reported in the WHO Pharmacovigilance Database**

Cutroneo Paola Maria, Sicily Pharmacovigilance Regional Centre,  
University Hospital of Messina, Italy

---

**P069 Tofacitinib-Induced Acute Pancreatitis**

Charfi Ons, Université Tunis el Manar Faculté de médecine de Tunis, Tunisia

---

**Pharmacogenomics – Patient-oriented pharmacovigilance**

---

**P070 Collection of Data for Detecting Adverse Drug Events in Smart Hospitals via Electronic Health Records, the GTT, Sensors and IoMT**

De Pretis Francesco, VTT Technical Research Center of Finland Ltd, Finland

---

**P071 Voriconazole-Induced Junctional Tachycardia: A Case Report**

Zghal Khaled, University of Sfax – Faculty of medicine of Sfax, Tunisia

---

**P072 Safety of Linagliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis**

Al-Fadel Nouf, Saudi Food and Drug Authority, Saudi Arabia

---

**P075 Drug Related-Problems in Hospitalised Patients with Chronic Kidney Disease**

Alruqayb Wadia S, University of Birmingham – School of Pharmacy,  
United Kingdom

---

**P076 Factors Associated with Patient-Experienced Burden of Adverse Drug Reactions of Non-Vitamin K Oral Anticoagulants**


Von Kreijfelt Gabriëlla, The Netherlands Pharmacovigilance Centre Lareb,  
Netherlands

---

**P077 Factors Affecting Clopidogrel Safety in the Montenegrin Population**

Vukicevic Veselinka, Institute for Medicines and Medical Devices, Montenegro

---

- 
- 
- P078** **Urinary MicroRNAs as Possible Biomarkers of Cisplatin-Induced Nephrotoxicity in Patients with Head and Neck Cancer**  
Moriel Patricia, State University of Campinas, Brazil
- 
- P079** **ABCC2 Gene Polymorphism and Adverse Reactions to Carboplatin and Paclitaxel Treatment in Non-small Cell Carcinoma Patients**  
Moriel Patricia, State University of Campinas, Brazil
- 
- P080** **Development of a Clinical Focus Pharmacovigilance System**  
Maza Jose Antonio, Instituto Nacional de Cardiología Ignacio Chávez, Mexico
- 
- P081** **Falling for Amiodarone – A Safety Analysis in Patients 60 Years and Older**  
Rudolph Annette, Uppsala Monitoring Center, Sweden
- 
- P082** **Pharmacogenomics (PGx) as a New Special Interest Group (SIG) at ISOP**  
Yue Qun-Ying, Uppsala Monitoring Centre, Sweden
- 
- P085** **Influence of the CYP450 Genetic Variation in Lipid Abnormalities with Clozapine Treatment: A Pilot Study in Patients with Psychiatric Disorder**  
Kleber Novais Pereira João, UNICAMP, Brazil
- 
- P086** **Clinical Pharmacokinetics and Pharmacodynamics of Moxifloxacin in Human Tuberculosis**  
Onasanya Seun, University of KwaZulu-Natal, Westville Campus, South Africa
- 
- P087** **Evaluation of Circulating MicroRNAs as Biomarkers of Hematological Adverse Reactions in Lung Cancer Patients Treated with Carboplatin and Paclitaxel**  
Moriel Patricia, State University of Campinas, Brazil
- 
- P088** **ABCB1 Transporter Allelic Variants and Dermatologic Adverse Reactions Related to Gefitinib Therapy in Lung Cancer Patients: A Pilot Study**  
Marília Berlofa Visacri, University of São Paulo, Brazil
- 
- P089** **Prescribing Patterns in Hospitalised Chronic Kidney Disease Patients: An Observational Study**  
Alruqayb Wadia S, University of Birmingham – School of Pharmacy, United Kingdom
- 
- P090** **Associations of Genetic Polymorphisms of the Transporters with Cisplatin-Induced Renal Adverse Reactions in Patients with Head and Neck Cancer**  
Marília Berlofa Visacri, University of São Paulo, Brazil
-

---

## Pharmacovigilance in healthcare emergency: lessons learned from COVID-19: vaccines – medicines

---

**P099** COVID-19 Vaccine Safety Surveillance and Causality Assessment of Adverse Events Following Immunisation: Lessons from South Africa

Meyer Johanna C, Sefako Makgatho Health Sciences University, South Africa

---

**P100** mRNA COVID-19 Vaccines Induced-Sudden Sensorineural Hearing Loss (SSNHL): Descriptive Analysis of French Pharmacovigilance Database (FPDB)

Bagheri Haleh, Faculty of Medicine, France

---

**P102** Upgrade of Croatian ADR e-Reporting System for COVID-19 Prospective Cohort Event Monitoring (ACCESS Project)

Dujmović Blažok Sandra, HALMED, Croatia

---

**P103** Psoriasis Induced by COVID 19 Vaccine

El Aidli Sihem, University of Tunis El Manar Faculty of Medicine of Tunis -UR17ES12, Tunisia

---

**P104** Incidence of ischaemic Stroke Following Comirnaty™ Administration: Comparison of Data from ASST GOM Niguarda and FAERS

Pascale Giulia, ASST GOM Niguarda, Italy

---

**P105** COVID Vaccines AEFI Monitoring in Tunisia: March 2021 to May 2022

Aouitni Imen, Centre national de pharmacovigilance, Tunisia

---

**P106** Maternal, Fetal, and Neonatal Outcomes among Pregnant Women Receiving COVID-19 Vaccination: the Preg-Co-Vax Study

Fraenza Federica, Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Italy

---

**P107** COVID-19 Vaccines and Reproductive Disorders: An Analysis of the European Database EudraVigilance

Riccardi Consiglia, Center of Pharmacovigilance and Pharmacoepidemiology, Campania Region, Naples, Italy

---

**P108** Pharmacovigilance Regulatory Actions by National Pharmacovigilance Centres in Fourteen Middle Eastern Countries Following COVID-19 Pandemic

Al-Zubiedi Sameh, School of Pharmacy/ The Univesity of Jordan, Jordan

---

**P109** Title of My Abstract: The Impact of SARS-CoV-2 on Mental Health. Focus on depression, Antidepressants Consumption and ADRs Signal Detection

Zerial Giovanna, Public Health Center of Pharmacovigilance, Friuli-Venezia Giulia Regional Office, Italy

---



- 
- 
- P110 Ivermectin-Induced Liver Injury when Used as Self-Medication in SARS-CoV-2 Infection**  
Oscanoa Teodoro Julio, Universidad Nacional Mayor de San Marcos, Peru
- 
- P111 COVID-19 Vaccine Pharmacovigilance Spontaneous Reporting in a Pandemic – Notes from a Small Country**  
Kenyon Susan, Ministry of Health, New Zealand
- 
- P112 Factors Influencing Patient Reporting of Adverse Reactions to Covid-19 Vaccines**  
Anton Christopher, West Midlands Centre for Adverse Drug Reactions, United Kingdom
- 
- P113 Digital Media and Pharmacovigilance: The SIMeF Pharmacovigilance Working Group Perspective**  
Stagi Lisa, Roche spa, Italy
- 
- P114 Previous Use of Proton Pump Inhibitors (PPI) in Hospitalized Patients and COVID-19 Mortality in Peru**  
Oscanoa Teodoro Julio, Universidad Nacional Mayor de San Marcos, Peru
- 
- P115 Utilization WHO Vaccine Hesitancy Tool to Assess the Refusal Rate of Routine Immunization Among Parents in Egypt**  
Rostom Hadir, ISoP Egypt Chapter – MSA University, Egypt
- 
- P116 Active Monitoring of Adverse Events in a Closed Population: Contributions from Colombia to COVID-19 Vaccines Safety**  
Vaca Claudia, National University of Colombia, Colombia  
Juanita Vahos Zambrano, National University of Colombia, Colombia
- 
- P118 COVID-19 Pandemic: A Surge in Counterfeit Medicines**  
Ussai Silvia, University of Cagliari, Italy
- 
- P119 Pharmacovigilance in Healthcare Emergency: Lessons Learned from COVID-19: Uganda**  
Byomire - Ndagije Helen Byomire, National Drug Authority, Uganda
- 
- P120 Impact of the Inclusion of Covid-19 Vaccines in the National Pharmacovigilance Database on the Measurement of Disproportionality**  
Talibi Ismail, Centre Antipoison et de Pharmacovigilance du Maroc, Morocco
- 
- P121 Evaluation of Suspected Adverse Reactions to COVID-19 Vaccines in Patients with Autism Spectrum Disorder: Analysis of VAERS Database**  
Di Carluccio Chiara, Italian National Institute of Health, Italy
-

- 
- P122** **Safety and Pharmacokinetic Profile of an Immunobiological Drug (anti SARS-Cov-2) in the Treatment of CoViD-19**  
Keller Guillermo Alberto, Administración Nacional de Laboratorios e Institutos de Salud (ANLIS Malbran), Argentina
- 
- P123** **Self-Medication Among Romanian Patients in General and in the Context of the COVID-19 Pandemic**  
Farcas Andreea, Iuliu Hatieganu University of Medicine and Pharmacy, Romania
- 
- P124** **Systemic COVID-19 vaccines Adverse Events Following Immunizations and Their Associated Factors: A Comparative Study Using Iraqi Consumers' Self-Reported Data**  
Al-Shimran Ban, Ministry of Health, Iraq
- 
- P125** **How Covid-19 Pandemic Affected the National Pharmacovigilance System in the Czech Republic**  
Kopecká Jana, State Institute for Drug Control, Czech Republic
- 
- P126** **Active Surveillance for Safety Monitoring of COVID-19 Vaccines in Saudi Arabia**  
Alhabardi Saja, Saudi Food and Drug Authority, Saudi Arabia
- 
- P127** **RESPIR'Nantes Study: What About the Safety?**  
Ruellan Anne-Lise, University Hospital Center, France
- 
- P128** **Covid-19 Vaccines: Is the Seriousness Criterion "Medically Important" Applied Correctly in Reports and Are There Differences between HCPs and Non-HCPs?**  
Scholz Irene, Swissmedic, Switzerland
- 
- P129** **Hepatic Disorders in Adults Associated with the Use of Ivermectin for SARS-CoV-2 Infection: A Pharmacovigilance Study in VigiBase**  
Oscanoa Teodoro Julio, Universidad Nacional Mayor de San Marcos, Peru
- 
- P130** **Strengthened Pharmacovigilance in France for Monitoring COVID-19 Vaccines and Therapeutics Toward a New Surveillance Era?**  
Pierron Evelyne, French National Agency for the Safety of Medicines and Health Products, France
- 
- P131** **Background Incidence in Spontaneous Reporting: Observed/Expected analysis of Myocarditis and Pericarditis with COVID-19 Vaccines in The Netherlands**  
Van Eekeren Rike, Netherlands Pharmacovigilance Centre Lareb, Netherlands
- 
- P133** **Role of the Hospital Pharmacist in the Evaluation of the Anti-COVID-19 Vaccine Safety Profile in the Post-Marketing Phase**  
Costantino Laura, Università degli Studi Magna Graecia di Catanzaro, Italy
-

- 
- 
- P134** **Sotrovimab – Flashes of Safety in COVID-19 Patients**  
Al Braik Fatima, UAE University, United Arab Emirates
- 
- P136** **Characteristics of Spontaneous Reports of Thrombosis with Thrombocytopenia Syndrome after COVID-19 Vaccines in the Netherlands**  
Van Eekeren Rike, Netherlands Pharmacovigilance Centre Lareb, Netherlands
- 
- P137** **How a Community Approach Can Drive Pharmacovigilance Activities in Low-Resource Settings during a Public Health Emergency: Lessons from COVID-19**  
Walker Ryan, University of Oxford, United Kingdom
- 
- P140** **Pharmacists' Engagement in the Adverse Drug Reactions Reporting Process During the COVID-19 Pandemic**  
Gavazova Evelina, Medical university of Plovdiv, Bulgaria
- 
- P141** **How to Handle a Sudden Tenfold Increase in ICSRs – Lessons Learned During the SARS-Cov-2 Pandemic**  
Samdal Hilde, Norwegian Medicines Agency, Norway
- 
- P143** **PharmaCovigilance: Role of the Pharmacist During COVID-19 Vaccination Campaign**  
Martignoni Isabella, Ospedale P. Pederzoli, Italy
- 
- P144** **Covid-19 Vaccines and Menstrual Disorders: Reports from Sardinian Regional Centre of Pharmacovigilance**  
Puddu Enrica Maria, University of Cagliari, Italy
- 
- P145** **Lessons Learned from COVID19: Enhancing the Discipline of Communications in Pharmacovigilance**  
Abatemarco Danielle, BeiGene, USA
- 
- P146** **Cross-Reactivity between Pfizer/BioNTech and Johnson Vaccines: A Case Report**  
Zghal Khaled, University of Sfax – Faculty of medicine of Sfax, Tunisia
- 
- P147** **COVID-19 Vaccines Surveillance: Asl Brindisi Pharmacovigilance Data**  
Pezzuto Benedetta, ASL Brindisi
- 
- P148** **Cerebro-Vascular Accident after Covid-19 Vaccination**  
El Aidli Sihem, Université Tunis El Manar/Faculté de Médecine de Tunis/UR17ES12, Tunisia
- 
- P149** **Myocarditis Related to SARS-CoV-2 Vaccines: Comparing Spontaneous Adverse Drug Reaction Reports with Intensive Monitoring of Nationwide Health-Registers in Sweden**  
Sundström Anders, Swedish Medical Products Agency, Sweden
-

- 
- P150** **Bell's Palsy and Covid-19 Vaccination**  
Charfi Ons, Université Tunis el Manar Faculté de médecine de Tunis /  
Unité de recherche UR17ES12., Tunisia
- 
- P151** **Rates of ADR Reports by Number of Administered SARS-CoV-2 Vaccination Doses in Sweden: Large Temporal Variations Especially in Consumer Reporting**  
Sundström Anders, Swedish Medical Products Agency, Sweden
- 
- P152** **Fixed Drug Eruption after ChAdOx1 nCoV-19 Vaccine**  
Jabri Fatma Ezahra, University of Tunis el Manar – Faculty of Medicine of Tunis:  
research unit UR17ES12, Tunisia
- 
- P153** **Adverse Reactions Associated with Comirnaty® Among Healthcare Professionals: A Cohort Event Monitoring Study in a Portuguese Hospital**  
Abrantes Joana Rita, Association for Innovation and Biomedical Research  
on Light and Image, Portugal
- 
- P154** **The Impact of the COVID-19 Pandemic on Spontaneous Reporting of Adverse Drug Reactions in the Central Region of Portugal**  
Abrantes Joana Rita, Association for Innovation and Biomedical Research  
on Light and Image, Portugal
- 
- P155** **Acute Angle Closure Glaucoma Following COVID-19 Vaccination**  
Daghfous Riadh, Department for the collection and analysis of adverse  
reactions, Tunisia
- 
- P156** **Do patients with SARS-CoV-2 Vaccine-Induced Chronic Urticaria Can Have Their Second Dose?**  
EL Aidli Sihem, Université Tunis El Manar/Faculté de Médecine de Tunis/  
UR17ES12, Tunisia
- 
- P157** **Establishing Patient Safety Monitoring in the Benefit-Risk Paradigm for Off-Label and Emergency Use of Medications for COVID-19: A Pharmacovigilance Perspective**  
Malikova Marina, Boston Medical Center, Boston University School  
of Medicine, USA
- 
- P158** **Active Pharmacovigilance in COVID-19 Patients: The Role of a Clinical Pharmacist in the Reporting of Adverse Drug Events**  
Hida Amina, Faculty of Medicine and Pharmacy of Rabat, Mohamed V Souissi  
University, Morocco
- 
- P159** **Urticaria Reactions after COVID-19 Vaccination: A Case Series**  
EL Aidli Sihem, Université Tunis El Manar/Faculté de Médecine de Tunis/  
UR17ES12, Tunisia
-

- 
- 
- P160** **Dermatomyositis Following Pfizer BioNTech Covid-19 Vaccination**  
El Aidli Sihem, Centre national de pharmacovigilance, Tunisia
- 
- P161** **Investigating a Signal of Acquired Haemophilia Associated with COVID-19 Vaccination: A Systematic Case Review**  
Cappello Emiliano, University Of Pisa, Italy
- 
- P162** **COVID-19 Vaccines and Thromboembolic Events with Thrombocytopenia: Data from Italian Pharmacovigilance Public Database**  
Bonaso Marco, University of Pisa, Italy
- 
- P163** **Leveraging Free-Text Information to Detect Duplicates in COVID-19 Vaccine Adverse Event Reports**  
Barrett Jim, Uppsala Monitoring Centre, Sweden
- 
- P164** **Enhanced Surveillance of Italian Vaccinovicilance Group During COVID-19 Pandemic**  
Petronzelli Fiorella, Italian Medicines Agency, Italy
- 
- P165** **Pharmacovigilance Contribution During National Mass Immunization Days**  
Lakhoua Ghozlane, Université Tunis El Manar/ Faculté de Médecine de Tunis/ Unité de recherche UR17ES12, Tunisia
- 
- P166** **The Italian Approach to Improve Standard Quality of ICSRs for COVID 19 Vaccines: From Patient Data to Causality Assessment**  
Petronzelli Fiorella, Italian Medicines Agency, Italy
- 
- P167** **COVID-19 Vaccination and Herpes Zoster/ Herpes Simplex Reactivation in the Elderly Population: A Pharmacovigilance Analysis**  
Battini Vera, Università degli Studi di Milano, Italy
- 
- P168** **Menstrual Changes Following COVID-19 Vaccination: A Pharmacovigilance Study Based on Spontaneous Reports of Adverse Events Following Immunization (AEFI)**  
Mosini Giulia, Università degli Studi di Milano, Italy
- 
- P169** **Risk Management Strategy to Promote the Uptake of COVID-19 Vaccination at a Tertiary Care Facility in Kenya**  
Aywak Dorothy, Kenyatta National Hospital, Kenya
- 
- P170** **Cases of Guillan Barré Syndrome Following COVID-19 Vaccination**  
Charfi Ons, Université Tunis el Manar Faculté de médecine de Tunis / Unité de recherche UR17ES12., Tunisia
- 
- P172** **Notoriety Bias in the Reporting of Adverse Events Following Immunization with COVID-19 Vaccines in the United States and Canada**  
Castillon Genaro, YolaRX Consultants, Canada
-

- 
- P173 Thromboembolic Events and COVID-19 Vaccine**  
Charfi Ons, Université Tunis el Manar Faculté de médecine de Tunis /  
Unité de recherche UR17ES12., Tunisia
- 
- P174 Adverse Effects of Hydroxychloroquine in COVID-19 Patients –  
a Review of Eudravigilance Database**  
Matos Cristiano, Instituto Politécnico De Coimbra, ESTESC-Coimbra Health  
School, Portugal
- 
- P175 Guillan-Barré Syndrome Following COVID-19 Vaccines:  
Analysis of the Vaccine Adverse Event Reporting System (VAERS) Database**  
Gaio Mario, University of Campania “L. Vanvitelli”, Italy
- 
- P176 Capillary Leak Syndrome and COVID-19 Vaccines: An Analysis  
of the European Spontaneous Reporting System Eudravigilance**  
Di Napoli Raffaella, University of Campania “Luigi Vanvitelli”, Italy
- 
- P177 European Safety Analysis of mRNA and Viral Vector COVID-19 Vaccines  
on Glucose Metabolism Events**  
Di Mauro Gabriella, Campania Regional Centre for Pharmacovigilance  
and Pharmacoepidemiology, Italy
- 
- P178 Safety of mRNA-Platform based Covid-19 Vaccines in Pediatric Population:  
An Analysis of the European Pharmacovigilance Database Eudravigilance**  
Ruggiero Rosanna, University of Campania Luigi Vanvitelli, Department  
of Experimental Medicine, Italy
- 
- P179 Pharmacovigilance Among Patients from the Perspective of Pharmacists:  
A Survey Study in Morocco**  
Oullada Oumaima, National Higher School of Electricity and Mechanics,  
ENSEM, Hassan II University, Morocco
- 
- P180 Vogt-Koyanagi-Harada Uveitis Following Covid-19 Vaccine**  
El Aidli Sihem, University of Tunis El Manar Faculty of Medicine of Tunis  
-UR17ES12, Tunisia
- 
- P182 Pattern of Adverse Effects of COVID-19 Vaccine Among the People  
of Bangladesh**  
Sharmin Elora, Bangabandhu Sheikh Mujib Medical University, Bangladesh
- 
- P187 Ecchymotic Plaques Induced by Spikevax: About 2 Cases**  
Zghal Khaled, University of Sfax – Faculty of medicine of Sfax, Tunisia
- 
- P188 Pharmacovigilance Before and After COVID-19 Pandemic: A 3-Years Analysis  
of Adverse Drug Reactions Reporting at the University Hospital of Catania**  
Drago Filippo, University of Catania, Italy
-

- 
- P189** **Adverse Drug Reactions Associated with Anti-Infective Agents Reported to the National Pharmacovigilance Centre in Saudi Arabia: A Descriptive Study**  
Alshehri Ghadah, Princess Noura Bint Abdulrahman University, Saudi Arabia
- 

### Risk communication

---

- P190** **Post-marketing Safety of Onasemnogene Apeparvovec and Nusinersen in Pediatric Population: Analysis of FAERS Database**  
Zinzi Alessia, University of Campania "Luigi Vanvitelli", Italy
- 
- P191** **Risk Communication: Ethionamide Mediated Gynecomastia**  
Mwesigwa Douglas, National Drug authority of Uganda, Uganda
- 
- P192** **Signal of Congestive Cardiomyopathy in Association with Olanzapine – Evidence Review from Pharmacovigilance Data**  
Alakeel Abdulaziz, Saudi Food and Drug Authority, Saudi Arabia
- 
- P193** **Isotretinoin Associated Risk of Blood Growth Hormone Decrease-Signal Review**  
S Almutairi Abdulrahman, SFDA, Saudi Arabia
- 

### Miscellaneous

---

- P393** **Phase-Wise Implementation of a Quality Management System to Improve the National Program for Adverse Events Following Immunization Surveillance in India**  
Joshi Jyoti, International Centre for Antimicrobial Resistance Solutions, Denmark
-